Head-to-head evidence
ICP-332 vs TDM-180935
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Atopic Dermatitis
Shared mechanism: TYK2/JAK1 · full Atopic Dermatitis pipeline
ICP-332
Developed by Beijing InnoCare Pharma Tech Co.
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: November 2026 · NCT06775860 (registry estimate)
TDM-180935
Developed by Technoderma Medicines
NCT06363461 · Phase 2 · completed
The study was randomized, double-blinded for participants and outcome assessors, and placebo-controlled, with change in the clinical m-EASI score as its primary endpoint. However, only 24 participants were enrolled and no primary endpoint results are available, so the trial provides limited evidence at this time.
Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: ICP-332's landscape · TDM-180935's landscape